SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
BRANFORD, Conn., Jan. 11, 2016 (GLOBE NEWSWIRE) -- BioXcel Corporation, a global leader in developing cloud-based big data platforms and transformative patient treatments, today announced a strategic big data collaboration with Centrexion Therapeutics to develop a portfolio of clinical pain therapeutic assets.
Centrexion is focused on developing and commercializing new treatments for chronic pain with better efficacy and safety than current treatment paradigms. Through this collaboration, Centrexion will leverage BioXcel's first-in-class Big Data Innovation Lab (BDI-Lab) to generate optimal therapeutic value at the intersection of pain biology and differentiated products with a higher probability of clinical and commercial success. This complex association of drugs and disease will involve big data analytics to decipher network pharmacology combined with deep expertise to generate product development blueprints for transformational pain therapeutics.
“This partnership allows us to combine our distinctive translational medicine approach with BioXcel’s world-class big data platform and discovery engine to develop new non-opioid therapies to treat chronic pain. We are pleased to partner with BioXcel on this important initiative and to deliver new and innovative solutions to patients in need,” said Kerrie Brady Chief Business Officer, Centrexion Therapeutics.
"We are excited to partner with Centrexion to support the development of innovative treatments for chronic pain," stated Frank D.Yocca Senior Vice President, CNS Research & Development, BioXcel Corporation. “Our Big Data Innovation Lab has diverse application in CNS diseases and across multiple therapeutic areas, as evident from our partnerships with Takeda, Alexion, Pronutria and many others. We expect that the combination of our respective capabilities will drive significant improvements in the speed and efficiency of Centrexion’s drug development initiatives.”
Under the terms of the agreement, BioXcel will receive an upfront payment, as well as development and commercial milestone payments. Financial details are not disclosed.
About BioXcel
BioXcel is a global leader in providing cloud-based Pharma big data solutions for discovering novel products and performance benchmarking of pipeline innovation and marketed products in all major therapeutic areas. Our first in class Big Data Innovation Lab is focused on the development of transformative patient treatments for strategic portfolio growth and leverages; PharmGPS® - a live analytics platform; an Integrated Center of Xcellence housing multidisciplinary scientific, commercial and medical teams; and a drug development team that offers deep domain expertise. Committed to innovation, product excellence and partner success, BioXcel's global collaborations span the biopharmaceutical ecosystem. We are headquartered in Branford, CT, USA with operations in Asia.
Contact: BioXcel Corporation Anita Ganjoo Corporate Communications Email: [email protected] Tel: 203 957 2487
